Onctotarget delivers wonderful news to thyroid patients

Dr. Carmelo Nucero has recently been interviewed by Oncotarget on their weekly podcast which is available now on iTunes. In the interview, Dr. Carmelo Nucero describes his cutting-edge research concerning papillary thyroid carcinoma and why hope can now be given to the cancer patient.

Oncotarget interviewed him because they are the world-renowned internationally peer-reviewed journal that focuses on the pathological results that come from cancer as well as the power of pathology in fighting and beating cancer. They focus on analyzing the impact that management programs have on the way a patient views their quality of life and personal satisfaction. They go on to show routinely how the positive outlook of the patient can increase the rate of successful cancer eradication. Because the work of Dr. Carmelo Nucero is directly in line with the mission of Oncotarget, they sought an interview with this genius oncologist. Listen to Oncotarget podcast on Stitcher.

Dr. Carmelo Nucero has been dealing with papillary thyroid carcinoma for his entire career as an oncologist. During his career though he saw the same story play out over and over again. Those who are diagnosed with papillary thyroid carcinoma are often treated with the drug vemurafenib which focuses on the mutated BRAF gene which is the cause of the cancer. However, the body eventually becomes drug-resistant against vemurafenib because it builds up an immunity in the BRAF gene. Dr. Carmelo Nucero would consistently have to tell his patients that the cancer has come out of remission and at this time is inoperable and incurable.

Learn more: https://www.ncbi.nlm.nih.gov/pmc/journals/1558/

He began dedicating his research time to find a way to stop the body from attacking vemurafenib. He created a think tank of oncologists from several specialties. Over time, he discovered the advanced breast medication drug palbociclib and began to wonder if that was a solution.

The drug palbociclib was often used to stop chemotherapy from destroying the lactation system in the breast. Dr. Carmelo Nucero wondered if he could use it to get the body to stop attacking vemurafenib. After a year of trials, he found out it was a success and soon the FDA will prove the treatment. Visit Soundcloud to listen an audio podcast of Oncotarget.

Leave a Reply

Your email address will not be published. Required fields are marked *